antibody

Goat anti-Tet2 (mouse) Antibody

MBS422646

0.1 mg

225 USD

polyclonal

goat

nonconjugated

mouse, rat

ELISA, enzyme immunoassay

Antibody

Goat anti-Tet2 (mouse) Antibody

Tet2

Tet2; tet oncogene family member 2; Ayu17-449; E130014J05Rik; MGC37385; mKIAA1546; methylcytosine dioxygenase TET2; probable methylcytosine dioxygenase TET2; tet oncogene 2; Tet2 antibody; tet oncogene family member 2 antibody; Ayu17-449 antibody; E130014J05Rik antibody; MGC37385 antibody; mKIAA1546 antibody; methylcytosine dioxygenase TET2 antibody; probable methylcytosine dioxygenase TET2 antibody; tet oncogene 2 antibody; Ayu17-449 antibody; E130014J05Rik antibody; methylcytosine dioxygenase TET2 antibody; MGC37385 antibody; mKIAA1546 antibody; probable methylcytosine dioxygenase TET2 antibody; tet oncogene 2 antibody; tet oncogene family member 2 antibody; Tet2 antibody; Tet2 (mouse)

methylcytosine dioxygenase TET2; Methylcytosine dioxygenase TET2; methylcytosine dioxygenase TET2; tet methylcytosine dioxygenase 2; Protein Ayu17-449

Tet2

Tet2; Tet2; Ayu17-449; mKIAA1546; E130014J05Rik; Kiaa1546

TET2_MOUSE

Polyclonal

Goat

Expected from sequence similarity: Mouse, Rat

1912

QPSLTSAQINFSQT

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA)

Peptide ELISA: Antibody detection limit dilution 1: 16000. Western Blot: Preliminary experiments gave an approx 80kDa band in lysates of cell line NIH3T3 after 1ug/ml antibody staining. Please note that currently we cannot find an explanation in the literature for the band we observe given the calculated size of 212kDa according to NP_001035490.2. The 80kDa band was successfully blocked by incubation with the immunizing peptide.

Immunogen: Peptide with sequence C-QPSLTSAQINFSQT, from the internal region of the protein sequence according to NP_001035490.2. Epitope: Internal region

157057152

NP_001035490.2

NM_001040400.2

64,499 Da

Epigenetic Regulation Of Gene Expression Pathway (1367459); Gene Expression Pathway (1367365); TET1,2,3 And TDG Demethylate DNA Pathway (1367461)

TET2: Catalyzes the conversion of methylcytosine (5mC) to 5- hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Defects in TET2 are a cause of polycythemia vera (PV). A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Defects in TET2 are a cause of myelodysplastic syndrome (MDS). A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Belongs to the TET family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Tumor suppressor; EC 1.14.11.n2; Oxidoreductase. Cellular Component: nucleus. Molecular Function: dioxygenase activity; DNA binding; ferrous iron binding; metal ion binding; oxidoreductase activity; zinc ion binding. Biological Process: 5-methylcytosine catabolic process; 5-methylcytosine metabolic process; cell cycle; chromatin modification; cytosine metabolic process; hemoglobin metabolic process; hemopoiesis; homeostasis of number of cells; kidney development; myeloid cell differentiation; myeloid progenitor cell differentiation; positive regulation of transcription from RNA polymerase II promoter; post-embryonic development; protein amino acid O-linked glycosylation; spleen development

0.1 mg

225 USD